JDD From the Vault: Estrogen Deficient Skin: A Topical Option for Postmenopausal Facial Aging
Have you seen this one? We’re highlighting a frequently visited JDD article from the vault that continues to draw attention.
Postmenopausal women often experience dryness, laxity, atrophy, and dullness due to estrogen-deficient skin (EDS), and many are seeking non-hormonal ways to address these changes. This 2018 JDD study evaluated a novel approach: topical methyl estradiolpropanoate (MEP), a “soft estrogen” that offers estrogen-like effects in the skin but is metabolized to an inactive compound, minimizing systemic risk.
In the 14-week study, MEP significantly improved clinical signs of aging compared to vehicle, with no hormonal side effects. It may offer dermatologists a safe, effective cosmeceutical option for patients concerned about postmenopausal facial aging.
J Drugs Dermatol. 2022;21(9); 1012-1013. doi:10.36849/JDD.6795
